Global Cardiomyopathy Market Report to 2031 – Featuring AstraZeneca, Merck, Novartis, Sanofi, and Abbott, Among Others –

DUBLIN–(BUSINESS WIRE)–The “Cardiomyopathy Market Size and Trends Report, including epidemiology and pipeline analysis, competitor assessment, unmet needs, clinical trial strategies and forecasts, 2021-2031″ has been added to drug pipelines from offer.

The publisher forecasts the cardiomyopathy therapeutics market within 7MM to grow from $1.6 billion in 2021 at a compound annual growth rate (CAGR) of 12.4% to $5.2 billion by 2031 .

Companies cited

  • Astra Zeneca

  • Merck

  • Boehringer Ingelheim

  • Novartis

  • Sanofi

  • Abbott

  • GlaxoSmithKline

  • Bristol Myers Squibb

  • MyoKardie

  • Pfizer

  • Cytokinetics

Main growth drivers:

  • Launch of Camzyos (Bristol Myers Squibb) and aficamten (Cytokinetics) on the 7MM

  • Expanded Entresto (sacubitril + valsartan) label to include CM


  • The cardiomyopathy market is currently highly generic and contains many off-label drugs, which provide affordable options with limited side effects. These factors create a rigid barrier for entry of new therapies, but the therapies in the pipeline will be successful due to their strong efficacy and safety profiles and the fact that they are cardiomyopathy-specific therapies. , rather than general cardiovascular drugs.

  • There is a growing emphasis on genetic screening and the development of genetic therapies, as cardiomyopathies are often inherited rather than acquired. Emprumapimod will be the first commercially available gene therapy, as it targets patients with DCM due to a mutation in the lamin gene. However, this drug will not generate significant revenue given the small size of the targeted patient population.

  • There is no cure for cardiomyopathies, but the symptoms of the disease are managed with generic cardiovascular drugs. This remains an area of ​​unmet need in the cardiomyopathy field.

  • Camzyos was the first new therapy launched in the cardiomyopathy market for several decades when it was commercialized in 2022. There is therefore a need for new therapies in this space, which should be met by the large pipeline.


  • Overview of cardiomyopathies, including epidemiology, disease etiology, and management.

  • Market revenue for leading cardiomyopathy drugs (including complementary off-label therapies used for metabolic benefits), annual cost of therapy, and forecasted sales for key late-stage pipeline drugs.

  • Key topics covered include assessment of current and developing therapies, unmet needs, current and future players, and market outlook for the US, 5EU, and Japan over the 10-year forecast period.

  • Pipeline analysis: new emerging trends in development and detailed analysis of late-stage drugs in development.

  • Analysis of the current and future competition in the global cardiomyopathy therapeutics market. In-depth review of key industry drivers, restraints and challenges.

Reasons to buy

The report will allow you to:

  • Develop and design your licensing and licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.

  • Develop business strategies by understanding the trends shaping and driving the global Cardiomyopathy Therapies market.

  • Generate revenue by understanding the key trends, innovative products and technologies, market segments, and companies that are likely to impact the global cardiomyopathy market in the future.

  • Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.

  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.

  • Track global cardiomyopathy therapies market drug sales from 2021 to 2031.

  • Organize your sales and marketing efforts by identifying the categories and market segments that present the maximum opportunities for consolidations, investments and strategic partnerships.

Main topics covered:

1 Cardiomyopathies: summary

2 Presentation

3 Overview of the disease

3.1 Etiology and pathophysiology

3.1.1 Etiology

3.1.2 Pathophysiology

4 Epidemiology

4.1 Context of the disease

4.1.1 Risk factors and comorbidities

4.2 Global and historical trends

4.3 Forecasting methodology

4.4 Cardiomyopathy Epidemiology Forecast (2021-2031)

4.5 Debate

5 Disease management

5.1 Overview of diagnosis and treatment

5.2 KOL Knowledge of Disease Management

6 Competitive evaluation

6.1 Overview

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Improvements in genetic testing and gene therapies

7.3 Curative rather than preventive treatment options

7.4 New drugs with specific targets

7.5 Appropriate diagnosis and treatment of patients with amyloid cardiomyopathy

8 R&D strategies

8.1 Overview

8.1.1 Label extension

8.1.2 Development of drugs with new targets

8.2 Clinical trial design

8.2.1 Quality of life parameters

9 Pipeline Assessment

9.1 Overview

9.2 Promising drugs in clinical development

10 Pipeline Assessment Analysis

10.1 Overview

10.2 Competitive Evaluation

11 current and future players

11.1 Overview

11.2 Transaction Trends

12 Market Outlook

13 Appendix

For more information about this Drug Pipelines report, visit

Source: Global Data

Comments are closed.